Monte Carlo Analysis of a Subcutaneous Absorption Insulin Glargine Model: Variability in Plasma Insulin Concentrations

Absorption kinetics of long acting insulin such as Glargine often shows significant intra and inter-individual variability. To add this variability to the pharmacokinetics model of Glargine, ranges of variation for Glargine model parameters were introduced into 1000 Monte Carlo simulations. This assessment and analysis portray the likely intra-individual and inter-individual variability that could be expected clinically. The Monte Carlo analysis thus defines a range and distribution of identified and validated model parameter variations to consider in designing a glycaemic control protocol using Glargine.

[1]  C. Hann,et al.  A Subcutaneous Insulin Pharmacokinetic Model for Computer Simulation in a Diabetes Decision Support Role: Validation and Simulation , 2008, Journal of diabetes science and technology.

[2]  Christopher E Hann,et al.  A Subcutaneous Insulin Pharmacokinetic Model for Computer Simulation in a Diabetes Decision Support Role: Model Structure and Parameter Identification , 2008, Journal of diabetes science and technology.

[3]  Christopher E. Hann,et al.  Stochastic modelling of insulin sensitivity and adaptive glycemic control for critical care , 2008, Comput. Methods Programs Biomed..

[4]  T. Heise,et al.  Albumin‐bound basal insulin analogues (insulin detemir and NN344): comparable time‐action profiles but less variability than insulin glargine in type 2 diabetes , 2007, Diabetes, obesity & metabolism.

[5]  Jesús Picó,et al.  Comprehensive pharmacokinetic model of insulin Glargine and other insulin formulations , 2005, IEEE Transactions on Biomedical Engineering.

[6]  R. Becker,et al.  Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique , 2005, Diabetologia.

[7]  L. Heinemann,et al.  Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. , 2004, Diabetes.

[8]  P. Brunetti,et al.  Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. , 2000, Diabetes.

[9]  D R Owens,et al.  Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. , 2000, Diabetes care.

[10]  L Heinemann,et al.  Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. , 2000, Diabetes care.

[11]  V. Jörgens,et al.  Absorption Kinetics and Biologic Effects of Subcutaneously Injected Insulin Preparations , 1982, Diabetes Care.